Catalyst
Slingshot members are tracking this event:
Bluebird Bio (BLUE) to complete Phase 1/2 study of LentiGlobin BB305 to subjects with beta-thalassemia major or severe sickle cell disease in December 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BLUE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 10, 2017
Occurred Source:
http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-updated-clinical-results-ongoing-phase-1
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1/2 Study, Lentiglobin, Lentiglobin Bb305, Beta-thalassemia, Sickle Cell Disease
